Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Investor Relations
Listing documents
Announcement and Circular Letter
Performance Report
Corporate Governance
Investor Contact
Media
About Us
Our Stories
Join Us
Contact Us
简
繁
EN
Home
Pipeline&Products
Science&Innovation
Recombinant IgG Cleaving Enzyme
Recombinant Human Hyaluronidase
Solutions
Media
About Us
Our Stories
Join Us
Contact Us
Investor Relations
Listing documents
Announcement and Circular Letter
Performance Report
Corporate Governance
Investor Contact
简
繁
EN
请输入您要查找的信息
热门关键词:
透明质酸酶
皮下给药
Announcement and Circular Letter
Responding to urgent patient needs
Innovating for diverse health challenges
Listing documents
Announcement and Circular Letter
Performance Report
Announcement and Circular Letter
2026.06.10
VOLUNTARY ANNOUNCEMENT - IND FOR SUBCUTANEOUS INFUSION OF BJ007 FOR INJECTION (SC) WAS APPROVED BY U.S. FDA
2026.06.04
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR KJ103 FOR INJECTION BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
2026.06.01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
2026.05.26
Articles of Association
2026.05.26
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
2026.05.26
(1) POLL RESULTS OF THE RESOLUTION PROPOSED AT THE ANNUAL GENERAL MEETING HELD ON MAY 26, 2026 (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ABOLISHMENT OF THE BOARD OF SUPERVISORS (3) RE-ELECTION AND APPOINTMENT OF DIRECTORS (4) APPOINTMENT OF CHAIRMAN OF THE SECOND SESSION OF THE BOARD (5) ELECTION OF THE EMPLOYEE REPRESENTATIVE DIRECTOR AND (6) CHANGE IN COMPOSITION OF BOARD COMMITTEES
2026.05.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
2026.05.04
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 26, 2026
«
1
2
3
4
»